Sugi Predict

Sugi Predict / Compounds / Histapyrrodine

Histapyrrodine

Histapyrrodine

SCHEMBL142300

c1ccc(CN(CCN2CCCC2)c2ccccc2)cc1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 8/20 0.54
▸ SLC6A3 Q01959 2/20 0.53
▸ TSHR P16473 2/20 0.49
▸ HTR7 P34969 2/20 0.48
▸ F2R P25116 1/20 0.47
▸ DPP7 Q9UHL4 1/20 0.46
▸ LTA4H P09960 1/20 0.45
▸ LMNA P02545 3/20 0.45
▸ CYP3A4 P08684 3/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ MLNR O43193 1/20 0.45
▸ CACNA1F O60840 1/20 0.45
▸ NR1I2 O75469 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histapyrrodine SCHEMBL316865 0.98 SIGMAR1 (0.53) SIGMAR1SLC6A3TSHRHTR7F2R
Histapyrrodine SCHEMBL1651354 0.97 SIGMAR1 (0.51) SIGMAR1SLC6A3TSHRHTR7F2R
SCHEMBL4930214 0.85 SIGMAR1 (0.65) SIGMAR1SLC6A3LTA4H
SCHEMBL10039145 0.81 SIGMAR1 (0.58) SIGMAR1SLC6A3DPP7LTA4H
SCHEMBL10798613 0.80 SIGMAR1 (0.46) SIGMAR1SLC6A3DPP7LMNAKMT2A
SCHEMBL13476319 0.79 SIGMAR1 (0.46) SIGMAR1SLC6A3LMNAMEN1KMT2A
Picoperine SCHEMBL137805 0.78 HRH3 (0.44) SIGMAR1TSHRLTA4HLMNAMAPT
SCHEMBL13306955 0.78 SIGMAR1 (0.73) SIGMAR1SLC6A3
Picoperine SCHEMBL209959 0.77 HRH3 (0.43) SIGMAR1LMNAMAPTALDH1A1SMN1; SMN2
Picoperine SCHEMBL1651072 0.77 HRH3 (0.43) SIGMAR1TSHRF2RLTA4HLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250041208-A1 NEW INJECTABLE COMBINATION FORMULATION NANEXA AB (SE) 2025-02-06 — — US claimed
EP-4444277-A1 NEW INJECTABLE COMBINATION FORMULATION Nanexa AB (SE) 2024-10-16 — — EP claimed
WO-2023105227-A1 NEW INJECTABLE COMBINATION FORMULATION NANEXA AB (SE) 2023-06-15 — — WO claimed
WO-2018189484-A1 MATRIX FOR SPECIFIC DETECTION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY Université d'Angers (FR) 2018-10-18 — — WO claimed
EP-2734514-B1 USE OF A THIOPHENE COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY UNIV ANGERS (FR) 2015-07-08 — — EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
WO-2014186623-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE BIOMED VALLEY DISCOVERIES (US) 2014-11-20 — — WO claimed
US-20140319331-A1 NEW USE FOR A COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR) 2014-10-30 — — US claimed
EP-2734514-A1 NEW USE FOR A COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY Centre National de la Recherche Scientifique (CNRS) (FR) 2014-05-28 — — EP claimed
WO-2013011234-A1 NEW USE FOR A COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) 2013-01-24 — — WO claimed
CN-100384909-C Polycarbonate material in alternating structure UNIV DALIAN SCIENCE & ENG (CN) 2008-04-30 — — CN claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
CN-1887934-A Polycarbonate material in alternating structure UNIV DALIAN SCIENCE & ENG (CN) 2007-01-03 — — CN claimed
EP-1696855-A1 DERMAL DRUG DELIVERY SYSTEM Medpharm Limited (GB) 2006-09-06 — — EP claimed
US-20060130266-A1 Dermal drug delivery system MEDPHARM LIMITED (GB) 2006-06-22 — — US claimed
WO-2005058226-A1 DERMAL DRUG DELIVERY SYSTEM MEDPHARM LIMITED (GB) 2005-06-30 — — WO claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 — — EP claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140319331-A1 NEW USE FOR A COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY CIAPIN1, SRMS, MMP7 SIGMAR1 4357/4885SLC6A3 1796/4885TSHR 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.